NFKB1 and mantle cell lymphoma: Thus, our data suggests that the full therapeutic potential of blocking constitutive NF-κB activity as a treatment strategy for MCL has yet to be fully realized and supports efforts invested towards the discovery and development of compounds capable of inhibiting bortezomib-resistant constitutive NF-κB activity with potency and specificity superior to POH.